EP0542756A1 - Method of introducing a peptide into the cytosol - Google Patents

Method of introducing a peptide into the cytosol

Info

Publication number
EP0542756A1
EP0542756A1 EP91911315A EP91911315A EP0542756A1 EP 0542756 A1 EP0542756 A1 EP 0542756A1 EP 91911315 A EP91911315 A EP 91911315A EP 91911315 A EP91911315 A EP 91911315A EP 0542756 A1 EP0542756 A1 EP 0542756A1
Authority
EP
European Patent Office
Prior art keywords
toxin
peptide
cytosol
mutant
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91911315A
Other languages
German (de)
French (fr)
Inventor
Sjur Olsnes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FORSKNINGSSTIFTELSEN DET NORSKE RADIUMHOSPITAL
Original Assignee
FORSKNINGSSTIFTELSEN DET NORSKE RADIUMHOSPITAL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FORSKNINGSSTIFTELSEN DET NORSKE RADIUMHOSPITAL filed Critical FORSKNINGSSTIFTELSEN DET NORSKE RADIUMHOSPITAL
Publication of EP0542756A1 publication Critical patent/EP0542756A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Definitions

  • the present invention is directed to a method of in- troducing a peptide into the cytosol, and more specifically to a novel principle in vaccine production against viruses, intracellular parasites and bacteria and against malignant cells.
  • MHC histocompati- bility antigens
  • MHC Class I MHC Class I
  • the common way today to immunize against such structures is to use attenuated live viruses that are able to enter cells and replicate such that the peptides in question are formed in the cells and can be presented at the cell surface. In this way the population of the relevant cytotoxic CD8 + cells is expanded and upon later exposure to the corres ⁇ ponding virulant virus strain, the organism has an immune protection.
  • toxin molecules that are of very low toxicity (Barbieri, J.T. & Collier, R.J. Infect. Immun. 55, 1647-1651 (1987)). If the toxins were able to carry s into cells additional peptide material, such non-toxic mutants could be useful for vaccine purposes to carry into the cytosol antigenic peptides (Cerundolo et al. Nature 345, 449 (1990)) that can be presented by Class I MHC antigens. Such antigenic sequences can be obtained from a number of viruses, bacteria o and parasites, and it is also possible to derive such struc ⁇ tures from certain malignant cells.
  • the present invention relates to a method of introducing a peptide into the cytosol by linking the peptide to a bacterial or plant toxin, or a mutant thereof. Further, the present invention relates to a method of preparing a vaccine by linking a peptide to a bacterial or plant toxin, or a mutant thereof to translocate the peptide into the cytosol for subsequent presentation at the cell surface by Class I MHC antigens to elicit a Class I restricted immune response and to expand the relevant population of CD8 + T-lymphocytes. Also, the present invention relates to vaccines which have been produced by the above-mentioned method, as well as the use of such vaccines against viruses, intracellular bacteria and para ⁇ sites, and against molecules associated with malignancies.
  • FIG. 1 N-terminal extensions of diphtheria toxin.
  • pBD-lS The coding region of the diphtheria toxin gene carrying a triple mutation changing Glu 148 to Ser, and where Gly 1 was replaced by initiator Met placed behind a T3 promotor to give pBD-lS (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S. : EMBO J. 8, 2843-2848 (1989)).
  • pBD-1 was cleaved with Ncol, and an oligonucleotide encoding the oligopeptide MGVDEYNEMPMPVN (referred to as B3) was inserted.
  • pGD-2 encodes diphtheria toxin with its natural signal sequence, MSRKLFASILIGALLGIGAPPSAHA (referred to as ss), after an SP6 promotor.
  • the plasmid was obtained by digesting pGD-1 (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)) with Hindlll and Pstl, removing the overhangs with S x -nuclease and religating to form pGD-2.
  • FIG. 2 Translocation to the cytosol of A-fragment with N-terminally added B3 oligopeptide.
  • pBD-1 and pB-B3-Dl were transcribed and translated in vitro.
  • the corresponding trans ⁇ lation products (DT and B3-DT) were added to Vero cells grow ⁇ ing as monolayers in 24-well microtiter plates and kept at 24°C for 20 min in the presence of 10 ⁇ M monensin (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)).
  • the cells were washed twice with Hepes medium and subsequently treated with 0.4 ⁇ g/ml TPCK (N-tosyl-L-phenyl- alanine chloromethyl ketone)-treated trypsin in Hepes medium containing 10 ⁇ M monensin for 5 min at 20°C.
  • the cells were washed and exposed to Hepes medium, pH 4.43, containing 10 mM Na-gluconate to increase the buffering capacity at the low pH. After 2 min at 37°C, the cells were washed with Hepes medium, pH 7.4, and then treated with 3 mg/ml pronase in Hepes medium, pH 7.4, containing 10 ⁇ M monensin for 5 min at 37°C.
  • TPCK N-tosyl-L-phenyl- alanine chloromethyl ketone
  • the cells which were detached from the plastic by the treatment, were recovered by centrifugation and washed once with Hepes medium containing 1 mM NEM (N-ethyl maleimide) and 1 mM PMSF (phenylmethylsulfonyl fluoride).
  • NEM N-ethyl maleimide
  • PMSF phenylmethylsulfonyl fluoride
  • the cells were lysed with Triton X-100 in phosphate buffered saline containing 1 mM PMSF and 1 mM NEM, nuclei were removed by centrifugation and the protein in the supernatant fraction was precipitated with 10% (w/v) trichloroacetic acid or immunoprecipitated with anti-B3 antibodies adsorbed to protein A-Sepharose.
  • FIG.3 Translocation to the cytosol of diphtheria toxin with signal sequence.
  • lane 3 the cells were treated as in lane 2, except that 6 times more translation product was used and the cells were then exposed to pH 4.8 and pronase as in Fig. 2.
  • the cells were lysed with Triton X-100 and the nuclei were removed.
  • the lysed cells were either analyzed with non-reducing SDS-PAGE (15% gel) directly (lanes 5-8) or they were treated with saponin and the membrane pellets (lanes 9 and 10) and the supernatant fractions (lanes 11 and 12) were analyzed separately.
  • Diphtheria toxin is synthesized by pathogenic strains of Corynebacterium diphtheriae as a single chain polypeptide.
  • the protein is easily split ( “nicked” ) at a trypsin-sensitive site to yield two disulfide-linked fragments, A and B (Pappen- heimer, A.M., Jr. Annu. Rev. Biochem. 46, 69-94 (1977)).
  • the B-fragment (37 kD) binds to cell surface receptors
  • the A-fragment (21 kD) is an enzyme that is trans ⁇ located to the cytosol where it inactivates elongation factor 2 by ADP-ribosylation and thus blocks protein synthesis (Van Ness, B.G., Hovard, J.B. & Bodley, J.W. J. Biol. Chem. 255, 10710-10716 (1980)).
  • the translocation which normally occurs across the limiting membrane of endosomes, is triggered by the low pH in the acidic vesicles (Draper, R.K. & Simon, M.I. J. Cell Biol.
  • a mutant toxin which contains a triple mutation changing Glu 148 , which is located in the enzymatically active site of the toxin, to Ser (Barbieri, J. T. & Collier, R.J. Infect. Immun. 55, 1647-1651 (1987)).
  • the modified toxin has strongly reduced toxicity.
  • toxin with B3 was selectively precipitated with anti-B3 (lane 4), but not with a control serum (lane 5). Toxin without B3 was not precipitated with anti-B3 (lane 3).
  • the dialyzed translation products were bound to Vero cells, nicked on the cells with low concentrations of trypsin, and then the cells were exposed to pH 4.8. Under these conditions part of the bound toxin was translocated to the cytosol and thereby became shielded against pronase added to s the medium (Moskaug, 3.0. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 263, 2518-2525 (1988)). In the case of diphtheria toxin as such, two fragments (MW 21 kD and 25 kD) were protected under these conditions (Fig.
  • toxin carrying its normal signal sequence (25 amino acids). As shown in Fig. 3, lane 2, this protein was nicked by trypsin into a 23.5 kD A-fragment and a 37 kD B- fragment. (In this experiment the toxin was only partially nicked. Partially nicked 125 I-labelled natural toxin is shown for comparison in lane 1). When the toxin with signal sequence was bound to cells, nicked, and then exposed to pH 4.8, two fragments (23.5 kD and 25 kD) were protected against pronase (lane 8).
  • Protected A-fragment with uncleaved signal sequence is also shown in lane 3, where the material was precipitated with an anti-diphtheria toxin serum which binds the whole toxin, the A-fragment, as well as whole B-fragment (see lanes 1 and 2), but not the 25 kD-fragment.
  • the pronase-treated cells were treated with saponin, the extended A-fragment was released to the medium (lanes 4 and 12), whereas the 25 kD fragment remained in the membrane fraction (lane 10).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Procédé permettant d'introduire un peptide dans le cytosol par liaison du peptide à une toxine bactérienne ou végétale, ou un mutant de celle-ci. Procédé de préparation d'un vaccin par liaison d'un peptide à une toxine bactérienne ou végétale, ou à un mutant de celle-ci de façon à effectuer la translocation dudit peptide dans le cytosol pour présentation ultérieure à la surface de la cellule par des antigènes de complexe majeur d'histocompatabilité (CMH) de classe I, afin de provoquer une réponse immunitaire limitée et d'augmenter la population de lymphocytes T CD8+. Vaccins obtenus grâce à ladite méthode et utilisation de ceux-ci contre les virus, les bactéries et les parasites intracellulaires ainsi que les molécules associées aux malignités.A method of introducing a peptide into the cytosol by binding the peptide to a bacterial or plant toxin, or a mutant thereof. Process for the preparation of a vaccine by binding of a peptide to a bacterial or plant toxin, or to a mutant thereof, so as to effect the translocation of said peptide into the cytosol for subsequent presentation on the surface of the cell by major histocompatability complex (MHC) class I antigens, in order to elicit a limited immune response and to increase the CD8 + T cell population. Vaccines obtained by said method and their use against viruses, bacteria and intracellular parasites as well as molecules associated with malignancies.

Description

Method of introducing a peptide into the cytosol
Field of the Invention
The present invention is directed to a method of in- troducing a peptide into the cytosol, and more specifically to a novel principle in vaccine production against viruses, intracellular parasites and bacteria and against malignant cells.
Background of the Invention
In the protection against pathogenic organisms and in their elimination antigen presentation by major histocompati- bility antigens (MHC) of class I plays an important role. Cytotoxic T-lymphocytes recognize cells that express foreign or unusual antigens on their surface and destroy the cells, which is important to eliminate an infection. The same mechan¬ ism is operating in the elimination of malignant cells. Anti¬ gen presentation by Class I MHC requires that the antigen to be presented is found in the cytosol or in the endoplasmic reticulum (Germain, R.N. Nature 322, 687-689 (1986)). Extern¬ ally added polypeptides therefore do normally not elicit a class I response. However, if the antigen is artificially introduced into the cytosol, presentation by MHC Class I may occur (Moore, M.W., Carbone, F.R. & Bevan, M.J. Cell 54, 777- 785 (1988)). The common way today to immunize against such structures is to use attenuated live viruses that are able to enter cells and replicate such that the peptides in question are formed in the cells and can be presented at the cell surface. In this way the population of the relevant cytotoxic CD8+ cells is expanded and upon later exposure to the corres¬ ponding virulant virus strain, the organism has an immune protection. The problems with this approach are partly due to the fact that the attenuated viruses may sometimes revert to virulence and partly to the problems of making attenuated viruses in many cases. Convenient and non-damaging methods to introduce into the cytosol foreign peptides, such as viral antigens, could therefore be useful for vaccine purposes to expand the relevant population of CD8+ MHC Class I restricted cytotoxic T-lymphocytes. The only established examples of external proteins that enter the cytosol are certain bacterial and plant toxins, such as diphtheria toxin, Pseudomonas aeruqinosa exotoxin A, ricin, abrin, viscumin, modeccin, Shigella toxin, cholera toxin,
5 pertussis toxin (Olsnes, S. & Sandvig, K. In: "Immunotoxins" (A.E. Frankel, ed.), Kluwer Academic Publishers, Boston 1988, pp. 39-73; Olsnes, S. & Sandvig, K. In "Receptor-mediated endocytosis" (I. Pastan & M.C. Willingham, eds.), Plenum Publ. Corp., 1985, pp. 195-234). Toxins of this group enter the o cytosol where they carry out enzymatic reactions that are deleterious to the cell or to the organism. By gene manipu¬ lations it is possible to form toxin molecules that are of very low toxicity (Barbieri, J.T. & Collier, R.J. Infect. Immun. 55, 1647-1651 (1987)). If the toxins were able to carry s into cells additional peptide material, such non-toxic mutants could be useful for vaccine purposes to carry into the cytosol antigenic peptides (Cerundolo et al. Nature 345, 449 (1990)) that can be presented by Class I MHC antigens. Such antigenic sequences can be obtained from a number of viruses, bacteria o and parasites, and it is also possible to derive such struc¬ tures from certain malignant cells.
It is an object of the present invention to provide a mechanism of translocating antigenic peptide sequences to the 5 cytosol in a safe way to expand the population of cytotoxic T- lymphocytes that are able to react with the corresponding antigen and eliminate those cells that are presenting the antigenic peptides. Although the entry mechanism for the different toxins mentioned above is in principle the same, it o has been worked out in most detail in the case of diphtheria toxin. This is the toxin we have used in most of our studies in connection with this application.
Summary of the Invention 5 we here demonstrate that an essentially non-toxic mutant of diphtheria toxin is able to translocate to the cyto¬ sol oligopeptides linked to its N-terminal end. The peptides we have studied are sufficiently different in sequence to allow the conclusion that a wide variety of peptides can be carried into the cells in the same way.
Thus, the present invention relates to a method of introducing a peptide into the cytosol by linking the peptide to a bacterial or plant toxin, or a mutant thereof. Further, the present invention relates to a method of preparing a vaccine by linking a peptide to a bacterial or plant toxin, or a mutant thereof to translocate the peptide into the cytosol for subsequent presentation at the cell surface by Class I MHC antigens to elicit a Class I restricted immune response and to expand the relevant population of CD8+ T-lymphocytes. Also, the present invention relates to vaccines which have been produced by the above-mentioned method, as well as the use of such vaccines against viruses, intracellular bacteria and para¬ sites, and against molecules associated with malignancies.
Figure Legends
FIG. 1. N-terminal extensions of diphtheria toxin.
A. The coding region of the diphtheria toxin gene carrying a triple mutation changing Glu148 to Ser, and where Gly1 was replaced by initiator Met placed behind a T3 promotor to give pBD-lS (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S. : EMBO J. 8, 2843-2848 (1989)). To obtain pB-B3-Dl, pBD-1 was cleaved with Ncol, and an oligonucleotide encoding the oligopeptide MGVDEYNEMPMPVN (referred to as B3) was inserted. pGD-2 encodes diphtheria toxin with its natural signal sequence, MSRKLFASILIGALLGIGAPPSAHA (referred to as ss), after an SP6 promotor. The plasmid was obtained by digesting pGD-1 (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)) with Hindlll and Pstl, removing the overhangs with Sx-nuclease and religating to form pGD-2.
B. The genes were transcribed in vitro and the mRNAs obtained were translated in rabbit reticulocyte lysate systems in the presence of [35S]methionine (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)). To remove reducing agents and to allow disulfide bridges to be formed, the translation mixture was dialyzed over night against PBS (0.14 M NaCl, 10 mM Na-phosphate, pH 7.4), and then for 4 h against Hepes medium (Dulbecco-modified Eagles medium wherein the bicarbonate had been replaced by 20 mM Hepes, pH 7.4). An aliquot of each sample was analyzed by polyacrylami.de gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE) under reducing conditions (Olsnes, S. & Eiklid, K. J. Biol. Chem. 255, 284-289 (1980)). In some cases the translation product was treated with protein A- Sepharose (Pharmacia, Sweden), which had previously been incubated with rabbit anti-B3 antiserum (lanes 3 and 4) or anti-ricin (lane 5). The adsorbed material was analyzed by SDS-PAGE. DT, translation product from pBD-1; B3-DT, trans¬ lation product from pB-B3-Dl; ss-DT, translation product from pGD-2.
FIG. 2. Translocation to the cytosol of A-fragment with N-terminally added B3 oligopeptide. pBD-1 and pB-B3-Dl were transcribed and translated in vitro. The corresponding trans¬ lation products (DT and B3-DT) were added to Vero cells grow¬ ing as monolayers in 24-well microtiter plates and kept at 24°C for 20 min in the presence of 10 μM monensin (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)). The cells were washed twice with Hepes medium and subsequently treated with 0.4 μg/ml TPCK (N-tosyl-L-phenyl- alanine chloromethyl ketone)-treated trypsin in Hepes medium containing 10 μM monensin for 5 min at 20°C. The cells were washed and exposed to Hepes medium, pH 4.43, containing 10 mM Na-gluconate to increase the buffering capacity at the low pH. After 2 min at 37°C, the cells were washed with Hepes medium, pH 7.4, and then treated with 3 mg/ml pronase in Hepes medium, pH 7.4, containing 10 μM monensin for 5 min at 37°C. The cells, which were detached from the plastic by the treatment, were recovered by centrifugation and washed once with Hepes medium containing 1 mM NEM (N-ethyl maleimide) and 1 mM PMSF (phenylmethylsulfonyl fluoride). In some cases, (lanes 1-3 and 8-10) the cells were lysed with Triton X-100 in phosphate buffered saline containing 1 mM PMSF and 1 mM NEM, nuclei were removed by centrifugation and the protein in the supernatant fraction was precipitated with 10% (w/v) trichloroacetic acid or immunoprecipitated with anti-B3 antibodies adsorbed to protein A-Sepharose. In other cases (lanes 4-7) the cells were treated with 50 μg/ml saponin in PBS containing 1 mM PMSF and 1 mM NEM to release translocated A-fragment, and then the proteins both in the pellet and in the supernatant fractions were precipitated with trichloroacetic acid. In all cases the precipitated material was analyzed by SDS-PAGE (13.5% gel) under non-reducing conditions.
FIG.3. Translocation to the cytosol of diphtheria toxin with signal sequence. Lanes 1-4: 125I-labelled natural toxin (wt-DT, lane 1) and in vitro translated pGD-2 ( [35S]methionine labelled toxin with signal sequence, ss-DT) were bound to Vero cells and nicked on the cells (lanes 1 and 2). In lane 3 the cells were treated as in lane 2, except that 6 times more translation product was used and the cells were then exposed to pH 4.8 and pronase as in Fig. 2. The cells were lysed with Triton X-100 and the nuclei were removed. The supernatants were incubated with protein A-sepharose that had been pre- incubated with rabbit anti-diphtheria toxin serum. The adsorb¬ ed material was analyzed by reducing (lanes 1 and 2) or non- reducing (lanes 3 and 4) SDS-PAGE (10% gel). In lane 4 the pronase-treated cells were treated with 50 μg/ml saponin and the material released to the medium was analyzed directly. Lanes 5-12: Translation products from pBD-1 (DT) and pGD-2 (ss-DT) were bound to Vero cells, nicked, exposed to pH 4.8 and then treated with pronase. The lysed cells were either analyzed with non-reducing SDS-PAGE (15% gel) directly (lanes 5-8) or they were treated with saponin and the membrane pellets (lanes 9 and 10) and the supernatant fractions (lanes 11 and 12) were analyzed separately.
Detailed Description Diphtheria toxin is synthesized by pathogenic strains of Corynebacterium diphtheriae as a single chain polypeptide. The protein is easily split ( "nicked" ) at a trypsin-sensitive site to yield two disulfide-linked fragments, A and B (Pappen- heimer, A.M., Jr. Annu. Rev. Biochem. 46, 69-94 (1977)). The B-fragment (37 kD) binds to cell surface receptors, whereas the A-fragment (21 kD) is an enzyme that is trans¬ located to the cytosol where it inactivates elongation factor 2 by ADP-ribosylation and thus blocks protein synthesis (Van Ness, B.G., Hovard, J.B. & Bodley, J.W. J. Biol. Chem. 255, 10710-10716 (1980)). The translocation, which normally occurs across the limiting membrane of endosomes, is triggered by the low pH in the acidic vesicles (Draper, R.K. & Simon, M.I. J. Cell Biol. 87, 849-854 (1980); Sandvig, K. & Olsnes, S. ___ s Cell Biol. 87, 828-832 (1980)). When cells with surface-bound toxin are exposed to acidic medium, translocation occurs from the cell surface (Sandvig, K. & Olsnes, S. J. Biol. Chem. 256, 9068-9076 (1981) ). We have in the presented examples used this artificial system, because it enables us to distinguish o between translocated and non-translocated material (Moskaug, 3.0. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 262, 10339-10345 (1987); Moskaug, J.0., Sandvig, K. & Olsnes, S. J. Biol. Chem. 263, 2518-2525 (1988)).
To avoid toxic effect on the cells by the diphtheria s toxin vector, a mutant toxin was used which contains a triple mutation changing Glu148, which is located in the enzymatically active site of the toxin, to Ser (Barbieri, J. T. & Collier, R.J. Infect. Immun. 55, 1647-1651 (1987)). The modified toxin has strongly reduced toxicity. 0
Examples
We used two variants of the mutated toxin gene, one without (pBD-1) (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S.: EMBO J. 8, 2843-2848 (1989)), and one with (pGD-2) 5 the natural 25 amino acids signal sequence (Fig. 1A). In one case, a foreign oligopeptide, termed B3, was linked to the N- terminal end of the toxin to yield the plasmid pB-B3-Dl.
The constructs, which were placed behind T3 or SP6 RNA- polymerase promotors, were transcribed and translated in vitro o (McGill, S., Stenmark, H., Sandvig, K. & Olsnes, S. :EMBO J. 8, 2843-2848 (1989)). In each case a major band corresponding to the full-length protein and only traces of material of lower molecular weights were obtained (Fig. IB). Toxin with signal sequence (lane 7) or with B3 (lane 1) migrated, as expected, 5 slightly more slowly than toxin as such (lanes 2 and 6).
Furthermore, toxin with B3 was selectively precipitated with anti-B3 (lane 4), but not with a control serum (lane 5). Toxin without B3 was not precipitated with anti-B3 (lane 3).
The dialyzed translation products were bound to Vero cells, nicked on the cells with low concentrations of trypsin, and then the cells were exposed to pH 4.8. Under these conditions part of the bound toxin was translocated to the cytosol and thereby became shielded against pronase added to s the medium (Moskaug, 3.0. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 263, 2518-2525 (1988)). In the case of diphtheria toxin as such, two fragments (MW 21 kD and 25 kD) were protected under these conditions (Fig. 2, lane 1), corresponding to the whole A-fragment (21 kD) and part of the B-fragment (25 kD out o of total 37 kD). The interfragment disulfide was reduced, apparently upon exposure to the cytosol (Moskaug, 3.0. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 262, 10339-10345 (1987)).
s Example 1
When the same experiment was carried out with toxin containing B3, two major fragments (25 kD and 22.5 kD) were protected in addition to small amounts of 21 kD fragment (lane 2). The latter probably represents A-fragment where B3 had o been cleaved off. When the exposure to low pH was omitted, no fragments were protected (lane 3). The 22.5 kD fragment was precipitated by anti-B3 (lane 9), but not with preimmune serum (lane 10). Protected A-fragment without the oligopeptide was not precipitated with anti-B3 (lane 8). The apparently higher 5 amount of protected A-fragment with B3 is due to more radio¬ activity incorporated, as B3 contains 3 methionines and the A- fragment alone 5.
When cells with translocated diphtheria toxin are treated with low concentration of saponin allowing cytoplasmic marker enzymes to leak out of the cells without dissolving the membranes, the translocated A-fragment is released into the medium, whereas the B-fragment-derived 25 kD polypeptide remains associated with the membrane fraction (Moskaug, 3.0. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 263, 2518-2525 (1988); Moskaug, J.0., Sletten, K. , Sandvig, K. & Olsnes, S. J. Biol. Chem. 264, 15709-15713 (1989); Moskaug, J.0., Sandvig, K. & Olsnes, S. J. Biol. Chem. 264, 11367-11372 (1989)). This indi¬ cates that the translocated A-fragment is free in the cytosol, whereas the 25 kD polypeptide is inserted into the membrane. Also most of the A-fragment containing B3 was released with saponin (lane 7) in the same way as normal A-fragment (lane 6), whereas the 25 kD fragment was associated with the membranes (lanes 4 and 5). Therefore, it appears that diph- theria toxin is able to translocate B3 (14 amino acids) to the cytosol.
Example 2
To test if also a larger oligopeptide could be trans- located, we chose toxin carrying its normal signal sequence (25 amino acids). As shown in Fig. 3, lane 2, this protein was nicked by trypsin into a 23.5 kD A-fragment and a 37 kD B- fragment. (In this experiment the toxin was only partially nicked. Partially nicked 125I-labelled natural toxin is shown for comparison in lane 1). When the toxin with signal sequence was bound to cells, nicked, and then exposed to pH 4.8, two fragments (23.5 kD and 25 kD) were protected against pronase (lane 8). Protected A-fragment with uncleaved signal sequence is also shown in lane 3, where the material was precipitated with an anti-diphtheria toxin serum which binds the whole toxin, the A-fragment, as well as whole B-fragment (see lanes 1 and 2), but not the 25 kD-fragment. When the pronase-treated cells were treated with saponin, the extended A-fragment was released to the medium (lanes 4 and 12), whereas the 25 kD fragment remained in the membrane fraction (lane 10).

Claims

Claims
1. A method of introducing a peptide into the cytosol, characterized by linking the peptide to a bacterial or plant toxin, or a mutant thereof.
2. A method of preparing a vaccine, characterized by linking a peptide to a bacterial or plant toxin, or a mutant thereof to translocate the peptide into the cytosol for subse¬ quent presentation at the cell surface by Class I MHC antigens to elicit a Class I restricted, immune response and to expand the relevant population of CD8+ T-lymphocytes.
3. The method according to claims 1 or 2, characterized by using a mutant of a bacterial or plant toxin which has been manipulated in such a way that it has lost its toxicity with¬ out having lost the ability to enter the cytosol and to carry additional peptide material into the cytosol.
4. The method according to claims 1 or 2-3, characterized by using a non-toxic mutant of diphtheria toxin or a related toxin such as ricin, abrin, modeccin, viscumin, volkensin, Pseudomonas aeruginosa exotoxin A, Shigella toxin, cholera toxin, E. coli heat labile toxin or pertussis toxin.
5. The method according to claims 1 or 2-4, characterized by using a non-toxic mutant of diphtheria toxin.
6. A vaccine, characterized by having been produced by a method according to claims 2-5.
7. The use of a vaccine according to claim 6 against viruses, intracellular bacteria and parasites, and against molecules associated with malignancies.
EP91911315A 1990-06-27 1991-06-26 Method of introducing a peptide into the cytosol Withdrawn EP0542756A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO902871 1990-06-27
NO902871A NO175188C (en) 1990-06-27 1990-06-27 Process for Preparing a Peptide Conjugate with the ability to penetrate cell cytosol

Publications (1)

Publication Number Publication Date
EP0542756A1 true EP0542756A1 (en) 1993-05-26

Family

ID=19893304

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91911315A Withdrawn EP0542756A1 (en) 1990-06-27 1991-06-26 Method of introducing a peptide into the cytosol

Country Status (8)

Country Link
EP (1) EP0542756A1 (en)
JP (1) JPH06503552A (en)
CA (1) CA2086342A1 (en)
FI (1) FI925869A0 (en)
HU (1) HUT63061A (en)
LT (1) LTIP835A (en)
NO (1) NO175188C (en)
WO (1) WO1992000099A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
US5935580A (en) * 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
DK0637335T3 (en) * 1992-04-21 2007-11-26 Pasteur Institut Recombinant mutants to induce specific immune responses
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US7422747B2 (en) 1997-10-07 2008-09-09 Loma Linda University Transgenic plant-based vaccines
US6777546B2 (en) 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
EP1254156A4 (en) * 2000-01-27 2003-05-21 Univ Loma Linda Transgenic plant-based vaccines
ATE438409T1 (en) 2000-09-15 2009-08-15 Pasteur Institut PROTEIN CONTAINING VECTORS FOR INTRODUCING MOLECULES INTO CD11B EXPRESSING CELLS
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US10988512B2 (en) * 2016-03-10 2021-04-27 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE25197T1 (en) * 1982-05-12 1987-02-15 Harvard College FUSIONED GENES ENCODING HYBRID PROTEIN, CLONING VECTORS CONTAINING THEM AND THEIR USE.
FR2532850B1 (en) * 1982-09-15 1985-12-20 Pasteur Institut IMMUNOGENIC CONJUGATES BETWEEN A HAPTENA AND A CARRIER MOLECULE DERIVED FROM A TOXIN, THE VACCINES CONTAINING THEM AND PROCESS FOR OBTAINING THEM
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
FR2636842B1 (en) * 1988-09-27 1994-06-10 Liege Universite Etat FUSION PROTEIN OF A SEQUENCE DERIVED FROM CHOLERIC TOXIN B SUBUNIT B AND A HETEROLOGOUS ANTIGEN HAVING IMMUNOGENIC PROPERTIES, RECOMBINANT NUCLEIC ACID CONTAINING VACCINE COMPOSITIONS CONTAINING NUCLEOTIDITE CODING SEQUENCE
AU657087B2 (en) * 1989-12-22 1995-03-02 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9200099A1 *

Also Published As

Publication number Publication date
LTIP835A (en) 1995-02-27
NO175188C (en) 1994-09-14
NO175188B (en) 1994-06-06
NO902871D0 (en) 1990-06-27
FI925869A (en) 1992-12-23
AU653158B2 (en) 1994-09-22
WO1992000099A1 (en) 1992-01-09
HUT63061A (en) 1993-07-28
CA2086342A1 (en) 1991-12-28
AU8000191A (en) 1992-01-23
JPH06503552A (en) 1994-04-21
HU9204125D0 (en) 1993-04-28
NO902871L (en) 1991-12-30
FI925869A0 (en) 1992-12-23

Similar Documents

Publication Publication Date Title
CA2691539C (en) Modified toxins
Antoine et al. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin
Collier Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century
Hwang et al. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli
Stenmark et al. Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol.
US8044188B2 (en) Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
Wick et al. Structure, function, and regulation of Pseudomonas aeruginosa exotoxin A
EP2178559B1 (en) Recombinant vibrio cholerae exotoxins
JP3755773B2 (en) Diphtheria toxin vaccine with mutant R domain
US6086900A (en) Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
van den Akker et al. Crystal structure of a new heat-labile enterotoxin, LT-IIb
EP0542756A1 (en) Method of introducing a peptide into the cytosol
JPH04501051A (en) Recombinant DNA-derived Bordetella toxin subunit analog
Madshus et al. Membrane translocation of diphtheria toxin carrying passenger protein domains
Nicholls et al. The structure of diphtheria toxin as a guide to rational design
Madshus et al. Entry of diphtheria toxin-protein A chimeras into cells.
De Haan et al. Enhanced delivery of exogenous peptides into the class I antigen processing and presentation pathway
JP2004531230A (en) General carrier for molecules targeting GB3 receptor expressing cells
KLINGENBERG et al. Ability of methotrexate to inhibit translocation to the cytosol of dihydrofolate reductase fused to diphtheria toxin
Idziorek et al. Low pH-induced changes in Pseudomonas exotoxin and its domains: increased binding of Triton X-114
AU653158C (en) Method of introducing a peptide into the cytosol
Stenmark et al. Association between diphtheria toxin A-and B-fragment and their fusion proteins
Tagge et al. Preproricin Expressed inNicotiana tabacumCellsin VitroIs Fully Processed and Biologically Active
Stenmark et al. Elimination of the disulphide bridge in fragment B of diphtheria toxin: effect on membrane insertion, channel formation, and ATP binding
EP1222202A2 (en) Ab5 toxin b subunit mutants with altered chemical conjug ation characteristics

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950727

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960903